208 related articles for article (PubMed ID: 31752110)
1. The Effect of Various Doses of Phenylalanine Supplementation on Blood Phenylalanine and Tyrosine Concentrations in Tyrosinemia Type 1 Patients.
van Ginkel WG; van Reemst HE; Kienstra NS; Daly A; Rodenburg IL; MacDonald A; Burgerhof JGM; de Blaauw P; van de Krogt J; Santra S; Heiner-Fokkema MR; van Spronsen FJ
Nutrients; 2019 Nov; 11(11):. PubMed ID: 31752110
[TBL] [Abstract][Full Text] [Related]
2. Emotional and behavioral problems, quality of life and metabolic control in NTBC-treated Tyrosinemia type 1 patients.
van Vliet K; van Ginkel WG; Jahja R; Daly A; MacDonald A; De Laet C; Vara R; Rahman Y; Cassiman D; Eyskens F; Timmer C; Mumford N; Bierau J; van Hasselt PM; Gissen P; Goyens PJ; McKiernan PJ; Wilcox G; Morris AAM; Jameson EA; Huijbregts SCJ; van Spronsen FJ
Orphanet J Rare Dis; 2019 Dec; 14(1):285. PubMed ID: 31801588
[TBL] [Abstract][Full Text] [Related]
3. LC-MS/MS method for simultaneous determination on a dried blood spot of multiple analytes relevant for treatment monitoring in patients with tyrosinemia type I.
la Marca G; Malvagia S; Materazzi S; Della Bona ML; Boenzi S; Martinelli D; Dionisi-Vici C
Anal Chem; 2012 Jan; 84(2):1184-8. PubMed ID: 22148291
[TBL] [Abstract][Full Text] [Related]
4. Daily variation of NTBC and its relation to succinylacetone in tyrosinemia type 1 patients comparing a single dose to two doses a day.
Kienstra NS; van Reemst HE; van Ginkel WG; Daly A; van Dam E; MacDonald A; Burgerhof JGM; de Blaauw P; McKiernan PJ; Heiner-Fokkema MR; van Spronsen FJ
J Inherit Metab Dis; 2018 Mar; 41(2):181-186. PubMed ID: 29170874
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Outcomes and Practical Considerations in the Pharmacological Management of Tyrosinemia Type 1.
van Ginkel WG; Rodenburg IL; Harding CO; Hollak CEM; Heiner-Fokkema MR; van Spronsen FJ
Paediatr Drugs; 2019 Dec; 21(6):413-426. PubMed ID: 31667718
[TBL] [Abstract][Full Text] [Related]
6. Pregnancy in an NTBC-treated patient with hereditary tyrosinemia type I.
Kassel R; Sprietsma L; Rudnick DA
J Pediatr Gastroenterol Nutr; 2015 Jan; 60(1):e5-7. PubMed ID: 23838819
[No Abstract] [Full Text] [Related]
7. Neuropsychological outcome of NTBC-treated patients with tyrosinaemia type 1.
De Laet C; Munoz VT; Jaeken J; François B; Carton D; Sokal EM; Dan B; Goyens PJ
Dev Med Child Neurol; 2011 Oct; 53(10):962-4. PubMed ID: 21745202
[No Abstract] [Full Text] [Related]
8. Long-term therapy with NTBC and tyrosine-restricted diet in a murine model of hereditary tyrosinemia type I.
Al-Dhalimy M; Overturf K; Finegold M; Grompe M
Mol Genet Metab; 2002 Jan; 75(1):38-45. PubMed ID: 11825062
[TBL] [Abstract][Full Text] [Related]
9. Laboratory monitoring of patients with hereditary tyrosinemia type I.
Schultz MJ; Netzel BC; Singh RH; Pino GB; Gavrilov DK; Oglesbee D; Raymond KM; Rinaldo P; Tortorelli S; Smith WE; Matern D
Mol Genet Metab; 2020 Aug; 130(4):247-254. PubMed ID: 32546364
[TBL] [Abstract][Full Text] [Related]
10. Dietary Considerations in Tyrosinemia Type I.
van Spronsen FJ; van Rijn M; Meyer U; Das AM
Adv Exp Med Biol; 2017; 959():197-204. PubMed ID: 28755197
[TBL] [Abstract][Full Text] [Related]
11. Treatment adherence in tyrosinemia type 1 patients.
González-Lamuño D; Sánchez-Pintos P; Andrade F; Couce ML; Aldámiz-Echevarría L
Orphanet J Rare Dis; 2021 Jun; 16(1):256. PubMed ID: 34082789
[TBL] [Abstract][Full Text] [Related]
12. Presumptive brain influx of large neutral amino acids and the effect of phenylalanine supplementation in patients with Tyrosinemia type 1.
van Ginkel WG; van Vliet D; Burgerhof JGM; de Blaauw P; Rubio Gozalbo ME; Heiner-Fokkema MR; van Spronsen FJ
PLoS One; 2017; 12(9):e0185342. PubMed ID: 28949985
[TBL] [Abstract][Full Text] [Related]
13. Neurological and Neuropsychological Problems in Tyrosinemia Type I Patients.
van Ginkel WG; Jahja R; Huijbregts SCJ; van Spronsen FJ
Adv Exp Med Biol; 2017; 959():111-122. PubMed ID: 28755189
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous quantification of succinylacetone and nitisinone for therapeutic drug monitoring in the treatment of Tyrosinemia type 1.
Sundberg J; Wibrand F; Lund AM; Christensen M
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Jan; 1072():259-266. PubMed ID: 29195145
[TBL] [Abstract][Full Text] [Related]
15. Clinical practice. NTBC therapy for tyrosinemia type 1: how much is enough?
El-Karaksy H; Rashed M; El-Sayed R; El-Raziky M; El-Koofy N; El-Hawary M; Al-Dirbashi O
Eur J Pediatr; 2010 Jun; 169(6):689-93. PubMed ID: 19882170
[TBL] [Abstract][Full Text] [Related]
16. Tyrosinemia type I treated by NTBC: how does AFP predict liver cancer?
Koelink CJ; van Hasselt P; van der Ploeg A; van den Heuvel-Eibrink MM; Wijburg FA; Bijleveld CM; van Spronsen FJ
Mol Genet Metab; 2006 Dec; 89(4):310-5. PubMed ID: 17008115
[TBL] [Abstract][Full Text] [Related]
17. Phenylalanine supplementation improves the phenylalanine profile in tyrosinaemia.
Wilson CJ; Van Wyk KG; Leonard JV; Clayton PT
J Inherit Metab Dis; 2000 Nov; 23(7):677-83. PubMed ID: 11117429
[TBL] [Abstract][Full Text] [Related]
18. Blood and Brain Biochemistry and Behaviour in NTBC and Dietary Treated Tyrosinemia Type 1 Mice.
van Ginkel WG; van Vliet D; van der Goot E; Faassen MHJR; Vogel A; Heiner-Fokkema MR; van der Zee EA; van Spronsen FJ
Nutrients; 2019 Oct; 11(10):. PubMed ID: 31623189
[TBL] [Abstract][Full Text] [Related]
19. First Scandinavian case of successful pregnancy during nitisinone treatment for type 1 tyrosinemia.
Äärelä L; Nevalainen PI; Kurppa K; Hiltunen P
J Pediatr Endocrinol Metab; 2020 May; 33(5):661-664. PubMed ID: 32238608
[TBL] [Abstract][Full Text] [Related]
20. Impaired cognitive functioning in patients with tyrosinemia type I receiving nitisinone.
Bendadi F; de Koning TJ; Visser G; Prinsen HC; de Sain MG; Verhoeven-Duif N; Sinnema G; van Spronsen FJ; van Hasselt PM
J Pediatr; 2014 Feb; 164(2):398-401. PubMed ID: 24238861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]